Quest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.
- Revenue
- +9.98%
- EPS
- +29.4%
- Free cash flow
- +6.21%
- Total debt
- −2.20%
Quarter to September 2026, against a year earlier
Follow DGX
Alert me
Quest Diagnostics Incorporated (DGX) Current ratio
Quest Diagnostics Incorporated's current ratio at the end of the quarter to 30 September 2026 was 1.7×, up 0.7× from fiscal 2025 (1.0×). Over the past ten years it has ranged from 0.9× (fiscal 2018) to 1.7× (fiscal 2020); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 2.3× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.0× | (5.34%) |
| FY2024 | 1.1× | (15.62%) |
| FY2023 | 1.3× | 6.80% |
| FY2022 | 1.2× | (21.74%) |
| FY2021 | 1.6× | (9.19%) |
| FY2020 | 1.7× | 37.60% |
| FY2019 | 1.3× | 33.69% |
| FY2018 | 0.9× | (24.25%) |
| FY2017 | 1.2× | (20.83%) |
| FY2016 | 1.6× | 21.97% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.7× | 6.85% |
| Jun 2026 | 1.6× | 34.95% |
| Mar 2026 | 1.2× | 12.91% |
| Dec 2025 | 1.0× | (7.45%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| GH Guardant Health, Inc. compare | 3.6× |
| RVTY Revvity Inc. compare | 2.7× |
| ILMN Illumina, Inc. compare | 2.6× |
| DGX Quest Diagnostics Incorporated | 1.7× |
| LH Labcorp Holdings Inc. compare | 1.4× |
| MTD Mettler-Toledo International, Inc. compare | 1.1× |
| MEDP Medpace Holdings, Inc. compare | 0.8× |
| IQV IQVIA Holdings Inc. compare | 0.8× |
| WAT Waters Corporation compare | 0.7× |
| Diagnostics & Research industry median | 2.3× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on DGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement